{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'used should be optimized for the evaluation of the type and site of disease. Furthermore, as with CT,', 'the modality used at follow-up should be the same as was used at baseline and the lesions should be', 'measured/assessed on the same pulse sequence. It is beyond the scope of the RECIST guidelines to', 'prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseases. Ideally,', 'the same type of scanner should be used and the image acquisition protocol should be followed as', 'closely as possible to prior scans. Body scans should be performed with breath-hold scanning', 'techniques, if possible.', 'Positron emission tomography will not be used for response assessment in this study.', 'Ultrasound: Ultrasound will not be used for response assessment in this study.', 'Bone scans will be used to assess the presence or disappearance of the bone component of bone', 'lesions. CT or MRI scan will be used to confirm ambiguous results of bone scans. Preferred method', 'for confirmation is MRI.', 'Time Point Assessments', 'The frequency and schedule of tumor assessments is defined in the protocol. The schedule is to be', 'maintained regardless of whether study treatment is held or discontinued. At baseline, tumors and', 'lymph nodes are classified and documented as target or nontarget per the definitions provided', 'above. It is possible to record multiple nontarget lesions involving the same organ as a single item', \"(eg, 'multiple liver metastases'). At all postbaseline (follow-up) evaluations the baseline classification\", '(target, nontarget) is to be maintained and lesions are to be documented and described in a', 'consistent fashion over time (eg, recorded in the same order on source documents). At each', 'assessment, a sum of the diameters (longest for nonnodal lesions, short axis for nodal lesions) for all', 'target lesions will be calculated and included in source documents. The baseline sum of the', 'diameters (SoD) will be used as reference to further characterize any objective tumor regression in', 'the measurable dimension of the disease. The lowest SoD (nadir) since (and including) the baseline', 'value will be used as reference for evaluating progression.', 'After baseline, target lesions should have the actual size documented, if possible, even if the lesions', 'become very small. If in the opinion of the radiologist the lesion has likely disappeared, 0 mm should', \"be recorded. If the lesion is present but too small to measure, an indicator for 'too small to measure'\", 'this should be included in source documents.', 'For target lesions, measurements should be taken and recorded in metric notation. All tumor', 'measurements must be recorded in millimeters.', 'Nontarget lesions are to be assessed qualitatively (present, resolved, or unequivocal progression)', 'and new lesions, if any, are to be documented separately.', 'At each evaluation, progression status is to be determined based upon the time point status for', 'target lesions, nontarget lesions, and new lesions.', 'Finding of new lesions should not be attributable to differences in scanning technique, change in', 'imaging modality or findings thought to represent something other than tumor. Necrosis of', \"preexisting lesions as part of a response to treatment should be excluded before defining a 'new'\", 'cystic lesion. A lesion identified on a follow-up study in an anatomical location that was not scanned', 'at baseline is considered a new lesion. If a new lesion is equivocal because of its small size, repeat', 'Page 54 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'scans need to confirm there is definitely a new lesion, and progression should be declared using the', 'date of the initial scan.', 'Time point progression can be based solely on bone scans if there is unequivocal evidence of new', 'bone scan lesions. New bone scan lesions will be considered malignant in the absence of correlative', 'imaging or clinical data that demonstrate lesions are not malignant. Follow up imaging may be', 'required to ensure new lesions are unequivocal. Increases in the density or size of bone scan lesions', 'present at baseline cannot be the basis of progression.', 'Time point response (TPR) criteria', 'Target Lesion TPR', 'Complete Response (CR) - Disappearance of all target lesions. All pathological lymph nodes (whether', 'target or non-target) must have reduction in short axis to < 10 mm.', 'Partial Response (PR) - At least a 30% decrease in SoD of target lesions, taking as a reference the', 'baseline SoD', 'Stable Disease (SD) - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for', 'PD.', 'Progressive Disease (PD) - At least a 20% increase in the SoD of target lesions, taking as a reference', 'the smallest (nadir) SoD since (and including) baseline. In addition to the relative increase of 20%, the', 'SoD must also demonstrate an absolute increase of at least 5 mm.', 'Not Applicable (NA) - No target lesion identified at baseline.', 'Unable to Evaluate (UE) - One or more target lesions are not imaged and the remainder of the SoD', 'compared with the nadir SoD does not meet the criterion for PD.', 'Non-Target Lesion TPR', 'Complete Response (CR) - Disappearance of all non-target lesions. All lymph nodes must be', 'nonpathological in size (<10 mm short axis)', 'Non-CR / Non-PD - Persistence of one or more non-target lesion(s)', 'Progressive Disease (PD) - Unequivocal progression of non-target lesions. Unequivocal progression', 'should normally trump target lesion status. It must be representative of overall disease status', 'change, not a single lesion increase', 'Not Applicable (NA) - No non-target lesions identified at screening', 'Unable to Evaluate (UE) - One or more non-target lesions are not imaged and the remaining', 'nontarget lesions do not meet the criterion for PD.', 'New Lesion TPR', 'Yes - Lesion present at follow-up visit either for the very first time or reappearing (ie, lesion was', 'present at baseline, disappeared at a follow-up visit and re-appeared later). On bone scan, a single', 'new lesion may not', 'be sufficient to qualify as PD. Confirmation should be obtained by performing CT or MRI of the area', 'of concern to confirm ambiguous results of bone scan. Preferred method for confirmation is MRI.', 'No - No new lesions present at follow-up.', 'Unable to Evaluate (UE) - Subject not assessed or incompletely assessed for new lesions.', 'Page 55 of 60']\n\n###\n\n", "completion": "END"}